Episode 045: Myeloma Series, Pt.6- Myeloma Treatment in Transplant Ineligible Patients
The Fellow on Call: The Heme/Onc Podcast
00:00
The Effects of DARA 2 MAB on Overall Survival
In the relapsed refractory setting, we had a trial where we looked at DARA 2 MAB combination therapy. And in that control arm, when they progressed, they got Dara 2 MAB on the back end and that still showed an overall survival benefit. So based on those results, it's thought that, yeah, it also makes sense to happen in the un-front setting and the upfront setting that the quadruplets will change the trajectory of the disease. But as we referenced before, you know, we have some data hinting that it might be, but not a lot of definitive data in these specific regiments.
Transcript
Play full episode
